BIOMARK ANNOUNCES EXERCISE OF WARRANTS AND GAIN DTC ELIGIBILITY FOR ITS COMMON SHARES

biomark announces exercise of warrants and gain dtc eligibility for its common shares

Vancouver, British Columbia – (April 21, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company’s private placement of units completed in April 2019, with the warrant exercise price of $0.20 per share.  All the warrants were exercised before the warranty maturity date of April 16, 2021. The gross proceeds to the company from the exercise of the warrants are expected to be approximately $400,000.00.

BioMark intends to use the net proceeds from the warrant exercise to fund ongoing clinical validation of its liquid biopsy platform and working capital for its clinical lab facilities in Québec as well as for other general corporate purposes.

“The infusion of equity indicates a strong appreciation from investors in BioMark’s fundamentals that will continue this momentum through the end of the year. This strengthening of the balance sheet is one more piece in our plan to accelerate the pre-commercialization of our early detection and screening diagnostics assays for lung cancers” said Rashid Bux, CEO of BioMark.

In addition, BioMark also would like to announce that its common shares will now be eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”). DTC is a subsidiary of the Depository Trust & Clearing Corporation, a US company that manages the electronic clearing and settlement of publicly traded companies. Through an electronic method of clearing securities, DTC eligibility simplifies the process of trading and transferring the Company’s common shares between brokerages in the United States.

BioMark’s common shares are now fully DTC eligible and will continue to trade under the ticker symbol “BMKDF” on the OTC market. “We are excited with obtaining DTC eligibility, as it represents an important step forward in broadening our shareholder base and building a strong presence for our company within the US capital markets sphere”, said Rashid Bux, CEO of BioMark.

Press Release – BIOMARK ANNOUNCES EXERCISE OF WARRANTS AND GAIN DTC ELIGIBILITY FOR ITS COMMON SHARES

Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.